AstraZeneca forges new biomarker deal; African-Americans may have unique Alzheimer's gene variation;

> AstraZeneca ($AZN) forged a new biomarker discovery deal with U.K.-based Oxford Cancer Biomarkers, focused on predicting who will respond best to a new cancer drug under development. More

> African-Americans appear to have a minor difference in their genes, compared to Caucasians, that can help identify the risk of Alzheimer's. Item

> Quest Diagnostics ($DGX) will use metabolomics biomarkers recently discovered by Matrix-Bio to develop a test that detects the recurrence of breast cancer. Item

> Emory University scientists spotted a new cerebrospinal fluid biomarker that can help distinguish between two major subtypes of frontotemporal lobar degeneration in living patients. Story (reg. req.)

> IVD tests that use molecular biomarkers seem to have increasingly long review periods compared to IVDs overall, Amplion Research has concluded. Item

Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.